Myocardial reperfusion injury and the challenging quest for its prevention.
Merx
Marc W
MW
Kelm
Malte
M
D000818:Animals; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005338:Fibrin Fibrinogen Degradation Products / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D010446:Peptide Fragments / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015427:Reperfusion Injury / Q000517:prevention & control*; D013552:Swine
D002316:Cardiotonic Agents; D005338:Fibrin Fibrinogen Degradation Products; D010446:Peptide Fragments; C033786:fibrinogen Bbeta (15-42)